medigraphic.com
Academia Mexicana de Neurología, A.C.

2008, Number 2

<< Back Next >>

Rev Mex Neuroci 2008; 9 (2)

Thyroid disorders in patients with multiple sclerosis

Uribe JPD, Nuñez OL

Language: Spanish
References: 27
Page: 131-135
PDF size: 50.16 Kb.


ABSTRACT

Introduction: The multiple sclerosis is a disease demyelinant of the nervous central system, where the oligodendrocytes produce an autoimmune physiopathogenia against the myelin. There has been reported a frequency of autoimmune disease of 29.9% in the relatives of firstly and the second degree of the patients with multiple sclerosis. Likewise the patients with multiple sclerosis have a major comorbidity with other immunological disorders as the arthritis rheumatoid, pernicious anemia, hypothyroidism autoimmune and diabetes mellitus type 1. Material and method: A observacional, transversal, descriptively and comparatively study was realized with 88 patients in the Servicio de Neurologia of the CMN “20 de Noviembre” from June, 2006 to March, 2007. The levels of T3L, T3T, T4L, T4T, antibodies anti-microsomales, anti-tiroglobulina and TSH’s levels were measured by techniques of specific radioinmunoenssay, test radioinmunometric and for an ultrasensitive method. Results: 58 (65.8%) patients presented the form appellant-sender, eight patients the primarily progressive form (9.2%). In whole, 21 patients (23.9%) presented thyroid alterations. Conclusion: The range of thyroid alteration founded (23.9%) in this study agrees with the reported in the literature, with major presence in the patients with multiple sclerosis that in the general population.


REFERENCES

  1. Alemany-R. Autoimmune diseases and Multiple sclerosis. Rev Neurol 2005; 40(10): 594-7.

  2. BrinarVV. CNS demyelinization in autoimmune diseases. Clin Neurol Neurosurg 2006; 108(3): 318-26.

  3. De Keyser J. Autoimmunity in multiple sclerosis. Neurology 1988; 38(3): 371-4.

  4. Karni A. Association with MS with thyroid disorders. Neurology 1999; 53(4): 883-5.

  5. Zych-Twardowska E. Blood levels of selected hormones in patients with MS. Med Sci Monit 2001; 7(5): 1005.

  6. Klapps S. Endocrine function in Ms. Acta Neurol Scand 1992; 85(5): 353-7.

  7. Wei T. The neuroendocrine axis in patients with Ms. Brain 1997; 120(Pt. 6): 1067-76.

  8. Petek-Balci A. Multiple sclerosis and Hashimoto thyroiditis: 2 cases. Neurologist 2005; 11(5): 301-4.

  9. Niederweiser G. Prevalence of autoimmune thyroiditis and nonimmune thyroid disease in MS. J Neurol 2003; 250(6): 672-5.

  10. Vecino MC. Prevalence of antimicrosomal antibodies in patients with MS. Arq Neuropsiquiatr 2004; 62(3A): 674-7.

  11. Annunziata P. Early synthesis and correlation of serum anti-thyroid antibodies and clinical parameters in MS. J Neurol Sci 1999; 168(1): 32-6.

  12. Sakuma A. Opticospinal form of MS and anti-thyroid antibodies. J Neurol 1999; 246(6): 449-53.

  13. Ioppoli C. Circulating thyroid and gastric parietal cell autoantibodies in patients with MS. Ital J Neurol Sci 1990; 11(1): 31-6.

  14. Fentiman IS. Primary hypothyroidism associated with interferon therapy in breast cancer. Lancet 1985; 1: 1166.

  15. Ronnblom J. Autoimmunity after alpha interpheron therapy for malignant carcinoid tumors. Ann Intern Med 1991; 115: 178-83.

  16. Silvestri F. Development of thyroid autoimmune disease in during long-term treatment of haematological malignancies with alphainterferon. Hametaologica 1994; 79: 367-70.

  17. Baudin EP. Reversibility of thyroid dysfunction induced by alphainterferon in chronic hepatitis C. Clin Endocrinol 1993; 39: 596-7.

  18. Monzani F. Discordant effect of IFN-beta1a therapy on anti-IFN antibodies and thyroid disease development in patients with multiple sclerosis. J Interferon Cytokine Res 2002; 22(7): 773-81.

  19. Schwid S. Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1b. Arch Neurol 1997; 54(9): 1169-90.

  20. Caraccio N. Long-term follow-up of 106 multiple sclerosis patients undergoing interferon-beta 1a or 1b therapy: predictive factors of thyroid disease development and duration. J Clin Endocrinol Metab 2005; 90(7): 4133-7.

  21. Martinelli V. Occurrence of thyroid autoimmunity in relapsing remitting multiple sclerosis patients undergoing interferon-beta treatment. Ital J Neurol Sci 1998; 19(2): 65-7.

  22. Durelli C. Autoimmune events during interferon beta-1b treatment for multiple sclerosis. J Neurol Sci 1999; 162(1): 74-83.

  23. Kreisler A. MS, interferon beta and clinical thyroid dysfunction. Acta Neurol Scand 2003; 107(2): 154-7.

  24. Bitsch A. Autoantibody synthesis in primary progressive multiple sclerosis patients treated with interferon beta 1b. J Neurol 2004; 251(12): 1498-501.

  25. Polman CH. Interferon beta-1b treatment does not induce autoantibodies. Neurology 2005; 64(6): 996-1000.

  26. Verdun E. Autoantibodies in multiple sclerosis patients before and during IFN-beta 1b treatment: are they correlated with the occurrence of autoimmune diseases? J Interferon Cytokine Res 2002; 22(2): 245-55.

  27. Colosimo C. No increase of serum autoantibodies during therapy with recombinant human interferon-beta1a in relapsing-remitting MS. Acta Neurol Scand 1997; 96(6): 372-4.




2020     |     www.medigraphic.com